儿童造釉细胞型颅咽管瘤非增强脑MRI肿瘤监测的准确性
本研究回顾性分析25例造釉细胞型颅咽管瘤患儿的系列MRI,由2名儿童神经放射学家对增强与非增强序列的囊性和实性成分分级,评估两者一致性及评分者间信度。结果显示囊性成分Cohen κ为0.961(95%CI 0.92-1.0),实性成分Cohen κ为0.80(95%CI 0.68-0.92),囊性成分一致率98.7%(74/75)和97.3%(73/75),实性成分一致率均为93.3%(70/75)。作者认为对于已知残留病灶的患儿,非增强MRI可能足以评估实性或囊性肿瘤生长。
要点
- 囊性成分增强与非增强MRI分级评分者间信度Cohen κ为0.961(95%CI 0.92-1.0)。
- 实性成分增强与非增强MRI分级评分者间信度Cohen κ为0.80(95%CI 0.68-0.92)。
- 囊性成分两种序列一致率分别为98.7%(74/75)和97.3%(73/75),实性成分均为93.3%(70/75)。
核心结论
- 对于已知残留病灶的造釉细胞型颅咽管瘤患儿,非增强MRI可能足以评估实性肿瘤或囊性生长。
研究设计与样本
- 回顾性研究,纳入25例造釉细胞型颅咽管瘤患儿,评估连续3次年度随访MRI,由2名儿童神经放射学家对增强与非增强序列的实性和囊性成分进行分级。
关键影像表现/征象
- 根据残留病灶实性和囊性成分特征对连续3次年度随访扫描进行分级。
- 增强与非增强MRI分级之间评分者间信度高。
诊断标准与关键数值
- 囊性肿瘤成分增强与非增强MRI分级评分者间信度Cohen κ为0.961(95%CI 0.92-1.0)。
- 实性肿瘤成分增强与非增强MRI分级评分者间信度Cohen κ为0.80(95%CI 0.68-0.92)。
- 囊性肿瘤成分增强与非增强MRI分级一致率:放射学家1为98.7%(74/75),放射学家2为97.3%(73/75)。
- 实性肿瘤成分增强与非增强MRI分级一致率:两名放射学家均为93.3%(70/75)。
临床应用与阅片要点
- 对于已知残留病灶的造釉细胞型颅咽管瘤患儿,非增强MRI可能足以评估实性肿瘤或囊性生长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Adamantinomatous craniopharyngioma (ACP) is a benign but histologically complex brain tumor that arises in the sellar or suprasellar region. Contrast-enhanced MRI of the brain is the standard of care for radiologic follow-up. Numerous studies have demonstrated gadolinium retention in the brain and body as a result of gadolinium-based contrast agent (GBCA) usage in MRI. While the clinical consequences of GBCA retention remain unknown, the concern for potential injury combined with advances in noncontrast imaging has promoted efforts to determine the necessity for contrast enhancement in the care of pediatric patients, particularly those with brain tumors. This study aims to evaluate the agreement and interrater reliability between noncontrast and contrast-enhanced MRI in the routine surveillance of children with ACP.
MATERIALS AND METHODS: We conducted a retrospective review of MR imaging for 25 patients with ACP undergoing routine imaging follow-up assessment. Pre- and postcontrast-enhanced MRI sequences were evaluated by 2 pediatric neuroradiologists. Three consecutive 1-year follow-up scans were graded based on the characteristics of the solid and cystic components of the residual lesion. Percent agreement and interrater reliability were determined for grading between contrasted and unenhanced MRI scans.
RESULTS: The mean age of patients was 8.72 ± 4.59 years, and the mean time between scans was 12.60 ± 4.08 months and 14.48 ± 7.77 months from the first to second and second to third scans, respectively. Interrater reliability between grading by using contrast-enhanced and unenhanced MRIs was high. We observed a Cohen κ of 0.961 (95% CI, 0.92-1.0) when evaluating the cystic tumor and a Cohen κ of 0.80 (95% CI, 0.68-0.92) when assessing the solid tumor. The percent agreement between grading by using contrast-enhanced and unenhanced MRI for the cystic tumor component was 98.7% (74/75) for radiologist 1, and 97.3% (73/75) for radiologist 2. The percent agreement between grading by using contrast-enhanced and unenhanced MRI for the solid tumor component was 93.3% (70/75) for both radiologists.
CONCLUSIONS: For children with ACP and known residual disease, noncontrast MRI may be sufficient for the assessment of solid tumor or cyst growth.
引用
- Chee K, Mirsky DM, Neuberger I, et al. Accuracy of Tumor Surveillance of Pediatric Adamantinomatous Craniopharyngioma Using Noncontrast Brain MRI. AJNR Am J Neuroradiol. 2025. PMID: 40998563. doi:10.3174/ajnr.A8928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。